- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02846675
Safety and Efficacy of Autologous SVF Cells in Treating Patients With Osteoarthritis
A Self-control Study: Safety and Efficacy of Autologous Adipose-Derived SVF Cells Delivered Intra-articularly in Patients With Osteoarthritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The adipose-derived SVF was obtained through disaggregation of lipoaspirate and resuspension of the SVF in 2 ml saline, with at least 50 million nucleated SVF cells and a mean viability of 85%, injected per single knee and the other knee treated with placebo.
Cell suspension and placebo will be injected using ultrasound guidance. Safety and knee function will be evaluated by questionaires monthly and MRI in every three months post-op.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Shanghai East Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Grade II or Grade III osteoarthritis using Kellgren-Lawrence grading scale (K-L Grade) as diagnosed using weight bearing X-ray, physician review, and/or pre-op MRI.
- Study Subjects must have failed a minimum of at least two conservative therapies, spanning a period of at least 3 months.
- Study Subjects must be willing to voluntarily give written Informed Consent to participate in the study and sign the Health Insurance Portability and Accountability Act (HIPAA) authorization before any study procedures are performed.
- Subjects will be in good health (ASA Class I-II) with a BMI < 35.
- Subjects must have continued pain in the knee despite conservative therapies for at least 3 months.
- Subjects with unilateral disease must present with symptomatic knee pain using the WOMAC subscale for pain.
- Subjects must speak, read and understand English.
- Subjects must be reasonably able to return for multiple follow-up visits.
Exclusion Criteria:
- Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study.
- Life expectancy < 6 months due to concomitant illnesses.
- Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
- Active infectious disease. Patients known to have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM > IgG) and/or syphilis will have an expert consultation as to patient eligibility based on the patient's infectious status
- Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
- Patients on chronic immunosuppressive transplant therapy
- Systolic blood pressure (supine) ≤90 mm Hg or greater than 180mmHg
- Resting heart rate > 100 bpm;
- Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
- History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
- Active clinical infection
- Unwilling and/or not able to give written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SVF treatment (random knee)
A random knee (left or right) of subjects will be treated with autologous SVF.
|
SVF will be obtained from lipoaspirates of subjects which will contain more than 5 millions nucleated cells.
Other Names:
|
Placebo Comparator: placebo treatment (the other knee)
The other knee of subjects will be treated with placebo.
|
a Placebo treatment without SVF cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: 6 months
|
Subjects will be monitored for adverse events
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Pain Scores on the WOMAC Scale at All Follow-up Visits
Time Frame: 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
Patients outcomes for pain will be scored through questionaires
|
1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
Change in Function Scores on the WOMAC Scale at All Follow-up Visits
Time Frame: 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
Patients outcomes for knee function will be scored through questionaires
|
1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
Change from baseline in MRI imaging
Time Frame: 3 months & 6 months
|
Knee function will be assessed by MRI at three time points: pre-op, 3 months and 6 months post-op
|
3 months & 6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DFSC-2014(CR)-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Mayo ClinicCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Sword Health, SAHospital da PreladaCompletedEfficacy of a Digital Biofeedback System for Home-based Rehabilitation After Total Joint ReplacementKnee Osteoarthritis | Hip OsteoarthritisPortugal
-
The Hawkins FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Massachusetts General HospitalNewton-Wellesley HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on autologous SVF
-
Shane A. ShapiroRecruitingVocal Fold ScarsUnited States
-
Michael H CarstensNational Autonomous University of Nicaragua; Ministerio de Salud de Nicaragua; Wake Forest UniversityCompleted
-
Mayo ClinicRecruitingOsteo Arthritis Knee | Degenerative Joint Disease of KneeUnited States
-
Kasiak Research Pvt. Ltd.UnknownCritical Limb IschemiaIndia
-
Dr. Himanshu Bansal FoundationCompletedNonunion of FractureIndia
-
Central Clinical Hospital w/Outpatient Health Center...Orenburg Regional Clinical Blood Donor CenterUnknownKnee OsteoarthritisRussian Federation
-
Tower Outpatient Surgical CenterUnknown
-
Elliot LanderCompletedAutoimmune Diseases | Osteoarthritis | Neurodegenerative Diseases | Emphysema | Erectile Dysfunction | CardiomyopathiesUnited States
-
Bangladesh Laser & Cell Surgery Institute & HospitalRecruitingChronic Kidney DiseasesBangladesh
-
AntriaCompletedAging | Wrinkles | LipoatrophyUnited States